**Table S4 ACR20 responders at 24 weeks by number of prior TNFi received (ITT population)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Abatacept** | **Placebo** | **Estimated difference (95% CI)** |
| 1 prior TNFi | 39/94 (41.5) | 24/92 (26.1) | 15.40 (2.00 to 28.81) |
| 2 prior TNFi | 8/31 (25.8) | 5/36 (13.9) | 11.92 (–7.18 to 31.02) |

Data are n/n (%) of patients unless indicated otherwise.

Early escape patients were imputed as non‑responders in the week 24 analysis.

ACR20, ≥20% improvement in American College of Rheumatology criteria; CI, confidence interval; ITT, intent-to-treat; TNFi, tumour necrosis factor inhibitor.